InforSense Ltd, the leading provider of next generation business and scientific intelligence tools, announced that the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King's College London will use InforSense's translational research solutions in Alzheimer's disease studies to advance the development of early diagnostic tools and develop personalized medicine treatments within mental health research. For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and 'omics' data through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis by non specialist end users.

"Our research centers on understanding the molecular and cellular events that take place in the brain in Alzheimer's disease and in particular we are working on blood based biomarkers to aid early diagnosis," said Simon Lovestone, professor of Old Age Psychiatry at King's College London and director of the Biomedical Research Centre for Mental Health. "The translational solutions that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyze data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification."

Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care. The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyze patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyze data using the VisualSense interactive web portal.

"InforSense is committed to providing leading edge translational research solutions to accelerate research into diseases such as Alzheimer's, breast cancer and multiple myeloma," said Jonathan Sheldon, chief scientific officer, at InforSense. "The Mental Health Biomedical Research Centre at SLaM and King's College London represents world-class research institutions engaged at the forefront of Alzheimer's research and we are looking forward to working closely with them. This relationship further demonstrates InforSense's market leading position in translational research informatics and growing use in healthcare analytics."

InforSense goes beyond traditional business intelligence to provide a completely integrated suite of agile, visual and predictive intelligence solutions, enabling organizations to gain business and scientific insights and optimize their business-critical decision-making processes.

The Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London is one of 12 national biomedical research centres created through the partnership of a leading National Health Service (NHS) provider and an outstanding university.